curriculum vitae milind javle, m.d. curriculum vitae milind javle, m.d. present title and...
Post on 27-Jul-2020
Embed Size (px)
Milind Javle, M.D.
PRESENT TITLE AND AFFILIATION Primary Appointment
Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment N/A
CITIZENSHIP United States
HOME ADDRESS 2007 Swift Blvd Houston, TX 77030 Cell: 281-630-5662
OFFICE ADDRESS The University of Texas MD Anderson Cancer Center 1515 Holcombe Blvd Unit Number: 426 Houston, TX 77030 Room Number: FC10.3026 Phone: 713-792-2828 Fax: 713-745-9926 Email: firstname.lastname@example.org
EDUCATION Degree-Granting Education
Grant Medical College, University of Bombay, India, Bombay, India, MD, 1991, Medicine Postgraduate Training
Clinical Internship, Internal Medicine, State University of New York (SUNY) Buffalo, Buffalo, NY, 1993-1994 Clinical Residency, Internal Medicine, SUNY Buffalo, Buffalo, NY, 1994-1995 Clinical Fellowship, Medical Oncology, Roswell Park Cancer Institute, Buffalo, NY, 1995-1998
CREDENTIALS Board Certification
Board Certification in Internal Medicine (ABIM), 1/1995-1/2019, Recertification Date: 1997 Medical Oncology, 5/2009-12/2019
Medical, TX, M5776, 2007 Inactive
Milind Javle, M.D.
Page 2 of 24
EXPERIENCE/SERVICE Academic Appointments
Medical Oncologist and Internist, Cancer Treatment Services, Geneseo, NY, 10/1998-9/2001 Assistant Professor, Roswell Park Cancer Institute, Buffalo, NY, 10/2001-12/2006 Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 1/2007-present
Administrative Appointments/Responsibilities N/A
Other Appointments/Responsibilities Reviewer, Data Monitoring and Safety Committee, Ohio State University Cancer Center, Columbus, OH, 2004-2007 Guidelines Panel Member, National Comprehensive Cancer Network (NCCN), n/a, 2005-2008 Scientific Program Committee Member, American Society of Clinical Oncology, n/a, 2007-present Senate Member, The University of Texas MD Anderson Cancer Center, Houston, 2009-present Associate Member, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX, 9/2009-8/2010 Vice Chair, The Cholangiocarcinoma Foundation - Clinical Science Advisory Board, Salt Lake City, UT, 2014-present Director, The Cholangiocarcinoma Foundation - International Cholangiocarcinoma Research Network, Salt Lake City, 2014-present
Endowed Positions N/A
Military or Other Governmental Service N/A
Institutional Committee Activities N/A
HONORS AND AWARDS Scientific Program Committee Track Leader, ASCO, 2008-2009 Three-year appointment award, The University of Texas MD Anderson Cancer Center, 2008-2011 Listing in 'Guide to America's Top Physicians', 2010-2011, 2010-2011, 2011-2012, 2012-2013 Tenure Track Appointment, The University of Texas MD Anderson Cancer Center, 2011-present Best Teaching Attending: 2005-6; Medical Oncology Fellows, Roswell Park Cancer Institute Early promotion in Internal Medicine, SUNY Buffalo Grant from AACR for research and travel to AACR/ASCO workshop in methods in Clinical Cancer Research, Park City Utah, 8/17-23, 1996, AACR Honors in Pharmacology, University of Bombay 1979 Physician of the Month: Hospice Buffalo: July 2004
RESEARCH Grants and Contracts
Funded Principal Investigator, 0.12 months, Ph2 single arm study of BGJ398 in patients with advanced or metastatic cholangio with FGFR2 gene fusions or other FGFR genetic alterations who failed
Milind Javle, M.D.
Page 3 of 24
or are intolerant to platinum-based chemo, 2014-0372, Novartis, 4/15/2014-4/14/2019, $347,781 ($347,781/year) Principal Investigator, Phase II randomized study of ACP-196 with gemcitabine + nab- paclitaxel for advanced pancreatic cancer, Acerta Pharma, 6/2015-6/2018 Co-Investigator, 0.12 months, Molecular Epidemiology of Gallbladder Cancer, 2017- 00054812, SINF, PI - Pant, Shubham, 9/1/2017-8/31/2019, $100,000 ($50,000/year) Principal Investigator, 0.6 months, Genomic/Immunological Heterogeneity of Intrahepatic Cholangiocarcinoma Research Network, CA180064, Department of Defense (DOD), 10/1/2019-9/30/2023, $1,411,312 ($915,758/year)
Pending Investigator, 0.12 months, Phase II trial of BTK inhibitor ACP - 196 with gemcitabine & abrarane for pancreatic cancer, The University of Texas MD Anderson Cancer Center, 3/2015- present
Completed Co-Investigator, 0.12 months, Cellular and Molecular Mechanisms of Gastrointestinal Cancers, 5P01CA130821-04, NIH/NCI, PI - Lopa Mishra, 9/1/2012-8/31/2014, $1,310,391 Principal Investigator, 0.12 months, A Phase I/Randomized Phase II Study of Gemcitabine + Erlotinib + MK-0646; Gemcitabine + MK-0646 and Gemcitabine + Erlotinib for Patients with Advanced Pancreatic Cancer, IISP33337, Merk and Company, 5/30/2013-5/29/2018 Co-Investigator, 0.6 months, Identification of a genetic signature of survival in patients with potentially curable pancreatic adenocarcinoma, IRG Katz Identification Gen, MDACC Institutional Research Grant, PI - Matthew Katz, 8/1/2013-7/31/2014 Principal Investigator, Targeting BAP1 in intrahepatic cholangiocarcinoma, The Cholangiocarcinoma Foundation, 7/1/2014-6/30/2016, $50,000 ($50,000/year)
Not Funded Principal Investigator, 0.6 months, Evaluating a novel bruton tyrosine kinase inhibitor in pancreatic cancer, Pancreatic Cancer Action Network, 7/1/2016-6/30/2019, $1,987,934 Principal Investigator, 1.2 months, Novel immunotherapy with Pembrolizumab and bruton tyrosine kinase inhibitor for familial pancreatic cancer, NIH/NCI, 9/1/2016-8/31/2020, $2,845,051 Principal Investigator, 5%, Association Between Somatic Genetic Mutations and Immune Biomarker Expression in Biliary Tract Cancer, Hope Foundation, 1/1/2017-9/30/2020, $62,500 ($50,000/year) Principal Investigator, 15%, Leveraging NQO1 bioactivatable drug for tumor selective use of PARPi, RP180119, Un of TX Southwestern Med Ctr Dallas, 3/1/2018-2/28/2021, $418,800 ($397,860/year) Co-Investigator, 0.24 months, Devising effective treatment for PDAC by co-targeting tumor cells and the tumor microenvironment, RP190026, Cancer Prevention & Research Institute of Texas (CPRIT), 2/1/2019-1/31/2023 ($285,000/year)
Principal Investigator, RAD001 + Erlotinib for Advanced Gemcitabine-Refractory Pancreatic Cancer. Phase II study, 2007-0666, 2007-2010, Novartis OSI Pharmaceuticals Principal Investigator, MK-0646 with Gemcitabine; MK-0646 with Gemcitabine and Erlotinib or Gemcitabine and Erlotinib. A randomized phase II study for pancreatic cancer, 2007-0910, 2007-present, $1,314,527, Merck
Milind Javle, M.D.
Page 4 of 24
Principal Investigator, Relevant Safety Study and Pharmacokinetic Determination of Cholecystokinin Type A Receptor VP16-GAL4-WPRE Integrated Systemic Amplifier Bcl12 Interacting Killer (BikDD nanoparticle) in CD1 Mice, 01-08-00531, 2008-2009, NCI Spore Principal Investigator, Preclinical study of SOM230B and Akt inhibition, CSOM230BUS11T, 2009-2010, Novartis Principal Investigator, (Local) Phase I Study of MEK inhibitor Array 162-111, 2009-0956, 2010-2013, Array Biopharma Principal Investigator, A phase II multicenter, single arm study of oral BGJ398 in adult patients with advanced or metastatic cholangiocarcinoma with FGFR2 gene fusions or other FGFR genetic alterations who failed or are intolerant to platinum-based chemotherapy (CBGJ398X2204), 2014-0372, 2014-2019, $502,954, Novartis Principal Investigator, Olaparib Monotherapy in Metastatic Pancreatic Cancer, 2015-0690, 2016-present, $274,205, Astra Zeneca Principal Investigator, Phase II study of olaparib for pancreatic cancer with BRCAness phenotype, 2015-0503, 2016-present, $494,912, Astra Zeneca Principal Investigator, Randomized study of ACP-196, 2015-0273, 2016-present, Acerta Principal Investigator, Single-arm, phase II proof of concept study of IDO-1 inhibitor epacadostat in combination with pembrolizumab in advanced pancreatic cancer with chromosomal instability/ homologous recombination repair deficiency (HRD), Contract Pending, 2016-present, Incyte Principal Investigator, A Multicenter, Double-Blind Randomized Placebo-Controlled Study of Varlitinib Plus Capecitabine Versus Placebo Plus Capecitabine in Patients with Advanced or Metastatic Biliary Tract Cancer as Second-Line Systemic Therapy, 2017-0481, 2017-2020 ($155,915/year), ASLAN Pharmaceuticals Principal Investigator, A Pivotal Trial of ARQ 087 in Subjects, 54445, PI - Milnd Javle, 2017- 2020 ($180,732/year), Basilea Pharmaceutica Ltd Principal Investigator, A Phase II Study of Gemcitabine, Cisplatin, and Abraxana in Advanced Biliary Ca, 2014-0524, 2018-2020 ($92,940/year), CELGENE Principal Investigator, A Phase II Study of siG12D LODER in Combination in Patients with Unresectable Locally Advanced Pancreatic Cancer (NCT01676259), 2018-0847, 2018-2020 ($57,531/year), Silenseed Ltrd Principal Investigator, 2019-0320 Phase 3 MULTICENTER, OPEN LABEL, RANDOMIZED, CONTROLLED STUDY OF THE ORAL INFIGRANTIB VERSUS GEMCITABINE WITH CISPLATIN IN SUBJECTS WITH ADNVACED/ METASTATIC OR INOPERABLE CHOLANGIOCARCINOMA WITH FGFR2 GENE FUSION, 57082, PI - MILIND JAVLE, 2019- present, QED THERAPUTICS
Patents and Technology Licenses Patents
N/A Technology Licenses
Grant Reviewer/Service on Study Sections Recovery Act Challenge Grant, NIH, mail reviewer, 2009 Lastgarten Foun